GlassScriptPhysician profile
Kort Christopher Knudson
NPI 1982627907
$7,787.14
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,248 · 2020: $1,567 · 2021: $1,356 · 2022: $616.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,176.16 | 2019-2022 | |
| Tosoh Bioscience, INC. | $1,078.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $682.58 | 2019-2022 | |
| Lilly USA, LLC | $639.18 | 2019-2022 | |
| Amgen INC. | $421.84 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $303.07 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $286.94 | 2019-2022 | |
| Mannkind Corporation | $243.08 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.91 | 2019-2022 | |
| Abbott Laboratories | $222.55 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $209.62 | 2020-2022 | |
| Amarin Pharma, INC. | $200.68 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $188.90 | 2019-2020 | |
| Radius Health, INC. | $148.18 | 2019-2022 | |
| Valeritas, INC. | $147.61 | 2019 |
Show all 44 companies
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kort Knudson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.